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Controlled Release of Neurotrophin-3 and Platelet-Derived Growth Factor
From Fibrin Scaffolds Containing Neural Progenitor Cells Enhances Survival
and Differentiation Into Neurons in a Subacute Model of SCI
Philip J. Johnson,* Alexander Tatara,* Alicia Shiu,* and Shelly E. Sakiyama-Elbert*†‡
*Department of Biomedical Engineering, Washington University, St. Louis, MO, USA
†Division of Plastic and Reconstructive Surgery, Department of Surgery,
Washington University School of Medicine, St. Louis, MO, USA
‡Center for Materials Innovation, Washington University, St. Louis, MO, USA

A consistent problem with stem/neural progenitor cell transplantation following spinal cord injury (SCI) is
poor cell survival and uncontrolled differentiation following transplantation. The current study evaluated the
feasibility of enhancing embryonic stem cell-derived neural progenitor cell (ESNPC) viability and directing
their differentiation into neurons and oligodendrocytes by embedding the ESNPCs in fibrin scaffolds containing growth factors (GF) and a heparin-binding delivery system (HBDS) in a subacute rat model of SCI.
Mouse ESNPCs were generated from mouse embryonic stem cells (ESCs) using a 4−/4+ retinoic acid (RA)
induction protocol. The ESNPCs were then transplanted as embryoid bodies (EBs, 70% neural progenitor
cells) into the subacute model of SCI. ESNPCs (10 EBs per animal) were implanted directly into the SCI
lesion, encapsulated in fibrin scaffolds, encapsulated in fibrin scaffolds containing the HBDS, neurotrophin3 (NT-3), and platelet-derived growth factor (PDGF), or encapsulated in fibrin scaffolds with NT-3 and
PDGF with no HBDS. We report here that the combination of the NT-3, PDGF, and fibrin scaffold (with
or without HBDS) enhanced the total number of ESNPCs present in the spinal cord lesion 2 weeks after
injury. In addition, the inclusion of the HBDS with growth factor resulted in an increase in the number of
ESNPC-derived NeuN-positive neurons. These results demonstrate the ability of fibrin scaffolds and the
controlled release of growth factors to enhance the survival and differentiation of neural progenitor cells
following transplantation into a SCI model.
Key words: Spinal cord injury (SCI); Neurotrophin-3 (NT-3); Platelet-derived growth factor (PDGF);
Controlled release; Embryonic stem cell-derived neural progenitor cell (ESNPC)

INTRODUCTION

The effectiveness of this spontaneous mechanism for regeneration may be limited in the case of substantial loss
of spinal cord interneurons at the site of injury and by
an environment that inhibits the ability of damaged supraspinal axons to regenerate over long distances (3).
As a treatment for SCI, stem cells offer a potential
cell source to replace lost cells. Neural progenitor cells
(NPCs) are stem cells that are restricted to differentiate
into one of the three major neural cell fates (10). The
limited differentiation potential of NPCs into only neural cell types has made them an attractive target for SCI
treatment. They can be obtained from sites of neurogenesis in the fetal or adult brain (e.g., SVZ) and spinal
cord (24), or derived from embryonic stem cells (ESCs)
through induction in culture (2). Prior studies of NPCs

Spinal cord injury (SCI) is a devastating condition that
results in significant damage to descending and ascending
axonal networks, glial and neuronal cell necrosis, and the
formation of an environment that is inhibitory to axonal
regeneration (13,22). Only limited spontaneous regeneration and functional recovery occurs after SCI. One
mechanism for spontaneous recovery that has been characterized in rodents is regeneration of damaged supraspinal cord axons over short distances to form local connections with surviving spinal cord interneurons (3,4,9).
It is hypothesized that the formation of these local connections facilitates the long-distance relay of supraspinal
signals and restores limited function following injury.
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transplanted into the injured spinal cord have found that
their survival is often poor and that the cells predominately differentiate into glia (7,8,21). One hypothesis for
the predisposition for glial differentiation following
transplantation into the injured spinal cord was given by
Cao et al., who have shown that the environment in the
spinal cord following injury inhibits differentiation of
NPCs into a neuronal fate (6). The differentiation of
transplanted NPCs into astrocytes may be problematic
because reactive gliosis is believed to be an inhibitor of
regeneration (23,26). SCI treatments utilizing stem cells
are currently limited by poor cell survival and uncontrolled differentiation in part as a result of the transplantation environment.
Nakamura et al. showed that given a favorable environment (injured neonatal spinal cord), transplanted
NPCs can survive, integrate with host tissue, and differentiate into neurons and oligodendrocytes (25). Furthermore, they found that repopulation of the injured spinal
cord with neurons and oligodendrocytes contributed significantly to plasticity and regeneration that resulted in
functional recovery. While the environment of the injured neonatal spinal cord, which is conducive to regeneration, differs significantly from the more inhibitory
adult spinal cord (7), these results illustrates that NPCderived neurons and oligodendrocytes can have a positive effect on functional recovery. The survival of transplanted NPCs following SCI can be enhanced using GF
delivered over 7 days from an osmotic pump (18). In
this study, the survival of transplanted cells was enhanced but the transplanted NPCs adopted a glial fate.
The difficulty of promoting the survival of transplanted
NPCs and controlling their differentiation into neurons
has led our group to investigate a novel scaffold for
transplantation.
The current study evaluated a method to enhance
ESNPC viability and direct their differentiation into a
population of neurons and oligodendrocytes following transplantation into a subacute model of SCI (17).
Embryonic stem cell-derived neural progenitor cells
(ESNPCs) were derived from mouse ESCs using a 4−/
4+ RA induction protocol (2). The ESNPCs were encapsulated in fibrin scaffolds with or without a heparinbinding delivery system (HBDS) that allowed for the
controlled delivery of neurotrophin-3 (NT-3) and platelet-derived growth factor (PDGF) (27). Fibrin scaffolds
containing the HBDS have been shown to control the
release of NT-3 and PDGF in vitro (32). At 2 weeks
following transplantation, the treated spinal cords were
harvested and evaluated for ESNPC viability, differentiation, and host spinal cord response. We report here that
transplanting ESNPCs within fibrin scaffolds containing
growth factor (GF) enhanced the total number of donorderived cells present in the spinal cords at 2 weeks after
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transplantation. Furthermore, the addition of the HBDS
to the fibrin scaffolds and GF resulted in an increase in
the number of ESNPC-derived NeuN-positive neurons.
MATERIALS AND METHODS
Embryonic Stem Cell Culture and Embryoid
Body Formation
CE3 mouse ESCs genetically engineered to express
green fluorescent protein (GFP) under the β-actin promoter were obtained from D. Gottlieb and were cultured
in T25 flasks (Fisher, Pittsburgh, PA) coated with a
0.1% gelatin solution (Sigma, St. Louis, MO) in the
presence of 1000 U/ml leukemia inhibitory factor (LIF;
Chemicon, Temecula, CA) and 10−4 M β-mercaptoethanol (BME; Invitrogen, Grand Island, NY) to maintain
their undifferentiated state. These cells were grown in
complete media consisting of Dulbecco’s modified Eagle media (DMEM) (Invitrogen) supplemented with
10% newborn calf serum (NBCS; Invitrogen), 10% fetal
bovine serum (FBS, Invitrogen), and 0.3 M of each of
the following nucleosides: adenosine, guanosine, cytosine, thymidine, and uridine (Sigma) and passaged at a
ratio of 1:5 every 2 days.
Undifferentiated ESCs were induced to form EBs
containing ESNPCs using a 4−/4+ RA induction protocol (2). ESCs were cultured in 100-mm petri dishes
(Fisher) coated with a 0.1% agar solution (MidSci, Saint
Louis, MO) in complete media in the absence of LIF
and BME for 4 days. RA (500 nM; Sigma) was added
to the complete media for the final 4 days of culture.
The media was changed every other day during induction. The resulting EBs contained 70% nestin-positive
NPCs (31).
Tissue Engineered Fibrin Scaffold Preparation
All materials were purchased from Fisher Scientific
(Pittsburgh, PA) unless otherwise noted. Fibrin scaffolds
were made as described previously by mixing the following components: human plasminogen-free fibrinogen
containing Factor XIII (10 mg/ml, Sigma), CaCl2 (5
mM), and thrombin (12.5 NIH U/ml, Sigma) in Trisbuffered saline (TBS, 137 mM NaCl, 2.7 mM KCl, 33
mM Tris, pH 7.4) (27). The bidomain affinity peptide
for the HBDS, denoted ATIII, was synthesized by standard solid phase Fmoc chemistry as described previously (27). In scaffolds containing the HBDS, ATIII
peptide (0.25 mM) and heparin (6.25 µM, Sigma, sodium salt from porcine intestinal mucosa) were added to
the fibrin polymerization mixture. In scaffolds containing ESNPCs, the EBs were added directly to the polymerization mixture prior to polymerization. Polymerized
fibrin scaffolds (10 µl in volume) were formed by ejecting the polymerization mixture from a 20-µl pipette tip
such that a sphere of the mixture formed on the tip of
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the pipette. The sphere was then allowed to polymerize
on the pipette tip for 5 min prior to implantation into
the injury site. A second 20-µl polymerization solution
devoid of EBs was then injected directly onto the sphere
already in the injury site and allowing it to polymerize
in the lesion site and stabilize the sphere in the injury
site.
In Vivo Studies: Dorsal Hemisection Subacute SCI
and Scaffold Implantation
All experimental procedures on animals complied
with the Guide for the Care and Use of Laboratory Animals and were performed under the supervision of the
Division of Comparative Medicine at Washington University. Long-Evans female rats (250–275 g, Harlan, Indianapolis, IN) were anesthetized using 4% isoflurane
gas (Vedco Inc., St Josephs, MO). The skin and muscle
overlying the spinal column were incised and dissected
away from the spinal column. Clamps attached to the
spinous processes and a rigid frame was used to immobilize the spinal column. A dorsal laminectomy was performed using fine rongeurs at level T-9 to expose the
spinal cord. A lateral slit in the dura was made, and
microdissection scissors mounted to a micromanipulator
were lowered into the spinal cord 1.2 mm from the dorsal spinal cord surface. Using the microdissection scissors, a lateral incision was made to form a complete
dorsal hemisection of the spinal cord. Finally the microdissection scissors were run through the incision to assure the hemisection was complete. The cord was then
covered with a piece of artificial dura (generous gift of
Synovis Surgical Innovations, St. Paul, MN), the muscles were sutured with degradable sutures, and the skin
was stapled close. Two weeks following initial injury
the lesion was reexposed, and scar tissue was removed
from the wound site of control and experimental groups
in preparation of fibrin scaffold transplantation.
A 2-week study was performed to evaluate the survival, differentiation, and host response to ESNPCs
transplanted in tissue engineered fibrin scaffolds.
ESNPCs were transplanted as EBs based on previous
work (30). Each EB contains approximately 10,000
ESNPCs. A 1-week study was previously performed to
evaluate the effect of cell number on survival and a dose
of 10 EBs was found to elicit robust ESNPC survival
and proliferation after transplantation (unpublished
data). As described above, scar tissue was removed and
either no treatment (control, n = 6), a fibrin sphere alone
(Fibrin, n = 6), 10 EBs placed directly in the lesion site
with no fibrin (10EB no Fibrin, n = 6), a fibrin sphere
containing 10 EBs (10EB + Fibrin, n = 8), a fibrin
sphere containing 10 EBs and HBDS with 125 ng NT-3
(Peprotech, Rock Hill, NJ), and 20 ng PDGF-AA (R&D
Systems, Minneapolis, MN) (10EB + DS + GF, n = 8),
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or fibrin sphere containing 10 EBs with 125 ng NT-3
and 20 ng PDGF-AA with no HBDS (10EB + GF no
DS, n = 8) were placed in the injury site. The untreated
control group received the same surgical removal of scar
tissue but no treatment with fibrin scaffolds or cells. Table 1 lists the experimental sample size for each analysis
technique used in the study.
Animals were given cefazolin (15 mg/kg, twice a
day) for 5 days following each surgical procedure as a
prophylactic against urinary tract infections. Bladders
were expressed manually twice a day until they regained
bladder control, approximately 5–6 days post-initial injury. Animals with transplanted ESNPCs were immune
suppressed with 10 mg/kg of cyclosporine A (Novartis,
East Hanover, NJ), because mouse ESCs were being
transplanted into rats. The animals were euthanized at
the end of each study using an overdose of Euthasol
(Virbac, France). After transcardial perfusion using 4%
paraformaldehyde (Sigma), spinal cords were dissected
and postfixed in 4% paraformaldehyde solution overnight. The cords were then cryoprotected in a 30% sucrose solution in phosphate-buffered saline (PBS) in
preparation for frozen sections. The spinal cord was embedded in Tissue-Tek OCT compound Mounting Media
(Sakura Finetek, Torence, CA) and cut into 20-µm sagittal sections using a cryostat.
Immunohistochemistry
Immunohistochemistry was used to assess the differentiation of the transplanted ESNPCs and morphological
aspects of the spinal cord from each experimental group.
Sections were washed with PBS and permeabilized with
0.1% Triton X-100 for 5 min. After washes in PBS, the
sections were blocked with 10% bovine serum albumin
(BSA, Sigma) and 2% normal goat serum (NGS,
Sigma). Primary antibodies against glial fibrillary acidic
Table 1. Experimental Sample Size (N) for Each
Experimental Analysis

Experimental
Groups
End point
10EB no Fibrin
10EB + Fibrin
10EB + DD + GF
10EB + GF no DS
Control
Fibrin

Stereology and
Differentiation
Analysis (N)*

Macrophage
Analysis (N)

2 weeks
6
8
8
8
—
—

2 weeks
6
8
8
8
6
6

Includes rats with no ESNPCs after 2 weeks.
*Stereology and differentiation analysis was not performed on Control
and Fibrin groups because ESNPCs were not transplanted in these
groups.
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protein (GFAP, rabbit polyclonal, recognizing astrocytes, 1:4; ImmunoStar, Hudson, WI), neuronal class III
β-tubulin (Tuj1, mouse monoclonal, recognizing neurons, 1:200; Covance Research Products, Berkeley, CA),
ED1 (mouse monoclonal, recognizing macrophages/
microglia, 1:100; Serotec, Oxford, UK), anti-oligodendrocyte marker O4 (O4, mouse monoclonal, recognizes
oligodendrocytes, 1:200; Millipore), anti-nestin (nestin,
mouse monoclonal, recognizes NPCs, 1:200; Millipore),
anti-neuronal nuclei (NeuN, mouse monoclonal, recognizes mature neurons, 1:500; Millipore), and anti-SSEA1 (SSEA-1, mouse monoclonal, recognizes mouse ESCs,
1:50; Millipore) were used to evaluate each section. Finally, appropriate secondary antibodies (Alexa Fluor
555, and 647 conjugated, 1:300; Invitrogen, Carlsbad,
CA) diluted with 2% NGS were used and each section
was stained with Hoechst nuclear stain (1:1000; Molecular Probes).
Stereological Analysis of Transplanted Cells
Sagittal sections of the frozen spinal cords were
taken, resulting in ⬃100 frozen serial sections. Every
12th section was then analyzed using stereological techniques, resulting in ⬃8 sections from each animal being
analyzed. Stereological cell counts of GFP+ cells to determine cell survival were performed on the 12th equidistant frozen section from each animal and counterstained with the nuclear dye Hoechst. To determine the
number of GFP+ mature neurons present at the end of
the 2-week study, stereological cell counts of GFP/
NeuN double-positive cells was performed on the 12th
equidistant frozen section from each animal. All stereological counts were performed using the Stereo Investigator Software (Version 7, MBF Biosciences, Williston,
VT) and verified with a Gunderson coefficient of error
less than 0.1. Animals in which ESNPCs were not seen
in the spinal cord at the end of 2 weeks were included
in the analysis as 0. Table 1 is a list of the experimental
sample size for each analysis technique used in the study
and indicates the inclusion of 0 for animals with no
ESNPCs.
Differentiation Analysis of Transplanted ESNPCs
Sagittal sections of the frozen spinal cords were
taken, resulting in ⬃100 frozen serial sections. Every
12th section was then analyzed resulting in ⬃8 sections
from each animal being analyzed. The lesion area of
every 12th serial spinal cord section was imaged at 100×
magnification using an Olympus IX70 microscope
(Olympus America, Melville, NY) and Magnafire Camera (Optronics, Goleta, CA). Imaging resulted in multiple 100× images per section that encompassed the entire
lesion site, which were later spliced together using Photoshop (Adobe, San Jose, CA) to yield a complete pic-

JOHNSON ET AL.

ture of the lesion. To ensure accurate quantification of
GFP-positive ESNPCs, control sections that did not receive cell transplants were imaged under the same conditions to account for auto fluorescence. The area of
GFP+ pixels (representing ESNPC-derived cells), and
the area of pixels positive for both GFP and one of the
five neural markers (Tuj1, GFAP, O4, or nestin; representing potential ESNPC-derived cell types) was measured in each section using the binary image processing
software Ia32 (Leco, St. Joseph, MI) (Fig. 1). An average area across all the sections for each animal was then
calculated to determine the average area of marker expression. An intensity threshold was set so that only pixels positive for the given marker were quantified within
the lesion. This analysis was performed in the place of
stereology because the nature of the tight organization
of the transplanted cells and the markers used made delineation between adjacent cells impossible (Fig. 2). Animals in which ESNPCs were not seen in the spinal cord
at the end of 2 weeks were included in the analysis as
0. Table 1 is a list of the experimental sample size for
each analysis technique used in the study and indicates
the inclusion of 0 for groups with no ESNPCs.
Macrophage/Microglia Profile Analysis
To assess the tissue response to the transplanted
ESNPCs, the lesion area was imaged at 40× magnification and individual 40× images of the lesion area were
spliced together to yield a complete picture of the lesion
area and surrounding intact cord. ED1 staining of macrophages and microglia was analyzed surrounding the
lesion site in six serial sections spaced 200 µm apart
from each rat to evaluate the tissue response to the fibrin
scaffolds. Macrophage/microglia response was analyzed
by using a program written in the Matlab Image Processing Toolbox (Mathworks, Natick, MA) as described previously (17). The program allowed the user to define the
lesion border based on GFAP staining. Based on this
border, the program generates line profiles of a specific
distance spaced 5 µm apart originating at the lesion border and preceding either rostrally or caudally from the
border. The program then analyzed the pixel intensity
along these lines and extracted relative ED1 fluorescence intensity as a function of distance from the glial
scar border (16). The analysis yielded a profile for each
sample. The ED1 intensity was normalized by a positive
control from each stained section. To concisely convey
these data, the normalized intensity was displayed at distances of 0, 50, 100, 200, and 400 µm rostral (−) and
caudal (+) to the lesion border. In Figure 3, the −0 and
+0 distance values indicate the normalized ED1 intensity directly at the border of the lesion and the adjacent
spinal cord tissue both rostral (−) and caudal (+) to the
lesion. The other distances, 50, 100, 200, and 400 µm
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Figure 1. The figure depicts the average area of expression analysis used to analysis differentiation in the current study. Fluorescent
images of transplanted ESNPCs shown here stained with β-tubulin (Tuj1, red, neurons) and green fluorescent protein (GFP, green)
were taken at 10× magnification. The images were then separated into images of different colored channels (red, green, and blue)
representing the different immunohistochemical stains (the red channel gives an image of Tuj1 staining and the green channel gives
the picture of GFP staining). The separated images were then thresholded to identify areas that were positively stained for the given
marker. The GFP image was then processed to remove any artifacts that might result in autofluorescence and thus could skew the
measurement (example shown here is the edge of an air bubble in the mounting solution). The processed images were then merged
using a Boolean operation that transfers those pixels that are positive for both GFP and Tuj1 into a merged image (light green
pixels in merged image). The area of these pixels was then quantified to determine an area of expression of the given marker, in
this case for Tuj1/GFP coexpression. Scale bar: 100 µm.

rostral (−) and caudal (+), extend out from the 0 distance. There are two 0 distance values because the injury
along the rostral to caudal axis is discontinuous and thus
there is a rostral value (−0) and a caudal value (+0).

Figure 2. An image of transplanted ESNPCs after 2 weeks
stained with β-tubulin III for neurons in red, GFP for transplanted ESNPCs in green, and Hoechst nuclear stain in blue.
The image shows the formation of rosette-like structures
within the transplanted EB that suggest early neural differentiation. The image also shows the congested nature of the transplants that makes accurate stereological counts of certain cell
markers impossible. Scale bar: 100 µm.

Statistical Analysis
All statistics were performed with analysis of variance (ANOVA, planned comparison post hoc test) using
Statistica (StatSoft, Tulsa, OK). Significance was determined to be p < 0.05. The statistical software automatically performs a Bonferroni correction for multiple comparisons.
RESULTS
Stereological Analysis of the In Vivo Survival
of ESNPCs and Neuronal Differentiation
The extent of ESNPC survival at 2 weeks after transplantation depended on the method of transplantation
and the presence of GF. In the 10EB no Fibrin group
only 50% of the animals were found to have any GFP+
cells present compared to 75% of the 10EB + Fibrin
group, 100% of the 10EB + DS + GF group, and 89%
of 10EB + GF no DS group (Table 2). The overall survival of the transplanted ESNPCs was quantified for
each group using stereological counts of GFP+ cells.
There was an increase in the number of GFP+ cells when
the ESNPCs were transplanted within fibrin scaffolds
with GF (10EB + DS + GF and 10EB + GF no DS)
compared to the ESNPCs implanted into the lesion site
alone (10EB no Fibrin, n = 3) and ESNPCs embedded
in fibrin with no GF (10EB + Fibrin, n = 6) (p < 0.05)
(Fig. 4A). The estimated number of GFP+ ESNPCs after
2 week suggests that the transplanted cells are not only
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Figure 3. Effect of ESNPCs on macrophage/microglia staining. The tissue response to the ESNPCs and fibrin scaffolds containing
ESNPCs was analyzed by measuring the intensity of ED1 staining as a function of distance from the lesion border. The analysis
yielded an ED1 profile for each experimental group that was normalized by a positive control. (A) ED1 profile for the control
(open bars, n = 6) and 10EB no fibrin group (filled bars, n = 6) 2 weeks following implantation. The normalized intensity is
displayed at distances of 0, 50, 100, 200, and 400 µm rostral (−) and caudal (+) to the lesion border. The 10EB no fibrin group
exhibited a significant decrease in normalized ED1 intensity at points adjacent to the lesion border (*p > 0.05 vs. control at same
distance). (B) ED1 profile for the control (open bars, n = 6) and 10EB + Fibrin group (filled bars, n = 8) 2 weeks following
implantation. The 10EB + Fibrin group exhibited a significant decrease in normalized ED1 intensity at points adjacent to the lesion
border (*p > 0.05 vs. control at same distance). (C) ED1 profile for the control (open bars, n = 6) and 10EB + DS + GF group
(filled bars, n = 8) 2 weeks following implantation. The 10EB + DS + GF group exhibited a significant decrease in normalized
ED1 intensity at points immediately adjacent to the lesion border (*p > 0.05 vs. control at same distance). (D) ED1 profile for the
control (open bars, n = 6) and 10EB + GF no DS group (Black bars, n = 8) 2 weeks following implantation. The 10EB + GF no
DS group did not exhibited a significant different normalized ED1 intensity at any distance from the lesion border (p > 0.05). Error
bars represent SD.

surviving but are proliferating. Based on the initial estimate of 1 × 105 cells per 10EBs, in the two groups without GF (10EB no Fibrin and 10EB + Fibrin) the number
of cells increased twofold [2.2 ± 1.1 × 105 and 2.0 ± 1.3 ×
105 cells, respectively (average ± SD)] and in the two
groups with GF (10EB + DS + GF and 10EB + GF no
DS) the number of cells increase roughly 100fold (12.0 ±
6.8 × 105 and 10.0 ± 7.8 × 105 cells, respectively).
The groups receiving ESNPCs were also stained with
the neuronal nuclei marker NeuN, which identifies mature neurons. The NeuN staining revealed a population
of ESNPCs that differentiated into mature neurons. The
differentiation was quantified using stereological counts
of the number of cells positive for NeuN and GFP (Fig.

4B). The analysis showed that the ESNPCs transplanted
in fibrin scaffolds containing the HBDS and GF (10EB +
DS + GF) had an increase in the number of ESNPCderived NeuN-positive mature neurons (p < 0.05) (Fig. 5).
Differentiation of Transplanted ESNPCs
Due to complications associated with acquiring accurate counts of the remaining neural cell markers using
stereology, a computer program was developed to quantify the expression of neural markers. The total area of
pixels positive for both GFP and the marker of interest
(Tuj1, GFAP, O4, nestin, or SSEA-1, staining shown in
Fig. 5) was measured in every 12th section in a series
of over 100 sections. The areas for each marker were
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Table 2. Presence of ESNPCs in the Spinal Cord After
2 Weeks

Experimental
Groups
10EB no Fibrin
10EB + Fibrin
10EB + DS + GF
10EB + GF no DS

Transplants
(N)

ESNPCs
at End
Point
(N)

With
ESNPCs
at End
Point

6
8
8
8

3
6
8
7

50%
75%
100%
89%

then averaged for each rat. The average area of GFP
expression for each experimental group was analyzed to
compare this method of analysis with the stereological
results of GFP+ cells. As with the stereological data, the
ESNPCs transplanted in fibrin with GF (10EB + DS +
GF and 10EB + GF no DS) had greater average areas of
GFP expression when compared to the ESNPCs transplanted alone (10EB no Fibrin) or the ESNPCs transplanted in fibrin without GF (10EB + Fibrin) (p < 0.05)
(Fig. 6A). Analysis of another neuronal marker (Tuj1),
using the average area of expression, showed similar
trends to those observed for the stereological counts of
NeuN and GFP staining. The average area of Tuj1 expression was increased for the ESNPCs in fibrin containing GF, and HBDS group (10EB + DS + GF) when
compared to ESNPCs transplanted alone (10EB no Fibrin) or ESNPCs in fibrin without GF (10EB + Fibrin)
(p < 0.05) (Fig. 6B). The average area of Tuj1 expres-
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sion of the ESNPCs in fibrin containing GF with no
HBDS was not significantly different from any other
group.
Two markers were used to evaluate the differentiation of ESNPCs into glia. The marker O4 was analyzed
to evaluate the differentiation of transplanted cells into
oligodendrocytes. O4 was expressed at considerably
lower levels compared to the neuronal marker Tuj1;
however, there were significant difference between
groups. The average area of O4 expression by ESNPCderived cells in fibrin with GF and HBDS (10EB + DS +
GF) was greater than all other groups (p < 0.05) (Fig.
7A). The expression of O4 by ESNPCs that were placed
directly in the lesion site (10EB no Fibrin) or embedded
in fibrin without GF (10EB + Fibrin) was very low. The
astrocytes marker GFAP was expressed by some ESNPCderived cells in each group. ESNPCs in fibrin with GF
(10EB + DS + GF and 10EB + GF no DS) had greater
average areas of GFAP expression compared to ESNPCs
transplanted directly into the lesion site (10EB no Fibrin) and ESNPCs in fibrin without GF (10EB + Fibrin)
(p < 0.05) (Fig. 7B). Finally, the expression of the NPC
marker nestin was used to evaluate those ESNPCs that
did not differentiate further and SSEA-1 was used to
evaluate the presence of undifferentiated mouse embryonic stem cells. The average area of nestin expression
did not reach the threshold for statistical significance for
differences between groups; however, when compared
to ESNPCs transplanted directly into the lesion site,
there was a trend toward increased nestin expression for
the groups with GF (10EB + DS + GF, p = 0.056 and

Figure 4. Stereological counts of GFP-expressing ESNPCs and GFP-expressing ESNPCs that also expressed the neuronal marker
NeuN 2 weeks after transplantation. (A) A count of GFP-expressing ESNPCs was performed to analyze survival and proliferation
of the transplants from each experimental group. (Note: y-axis is multiplied by 105). The ESNPCs transplanted in fibrin scaffolds
containing NT-3 and PDGF (10EB + DS + GF (n = 8) and 10EB + GF no DS (n = 8)) had a significantly higher count of ESNPCs.
Error bars are SD. *p < 0.05 versus 10EB no Fibrin (n = 6) and 10EB + Fibrin (n = 8). (B) A count of GFP-expressing ESNPCs
that also expressed the marker for mature neurons, NeuN, was performed to analyze neuronal differentiation. (Note: y-axis is
multiplied by 104). The ESNPCs transplanted in fibrin scaffolds containing NT-3, PDGF, and the HBDS [10EB + GF + DS (n =
8)] had a significantly higher count of NeuN-positive ESNPCs when compared to ESNPCs transplanted alone (10EB no Fibrin)
and ESNPCs transplanted in fibrin scaffolds alone (10EB + Fibrin). Error bars represent SD. *p < 0.05 versus 10EB no Fibrin
(n = 6) and 10EB + Fibrin (n = 8).
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Figure 5. The figure depicts in vivo fluorescent imaging of transplanted cells 2 weeks following transplantation. (A) NeuN (red,
neuronal nuclei) staining showing the expression of NeuN by transplanted cells (GFP, green) cross-stained with Hoechst nuclear
stain (blue). (B) Tuj1 (red, neuronal cytoskeletal) staining showing the expression of Tuj1 by transplanted cells (GFP, green) crossstained with GFAP (blue, astrocytes). (C) Nestin (red, ESNPC) staining showing the expression of nestin by transplanted cells (GFP,
green) cross-stained with GFAP (blue, astrocytes). (D) O4 (red, early oligodendrocyte marker) staining showing the expression of
O4 by transplanted cells (GFP, green) cross-stained with GFAP (blue, astrocytes). (E) SSEA-1 (red, mouse embryonic stem cell
marker) staining showing the expression of SSEA-1 by transplanted cells (GFP, green) cross-stained with Ki67, the nuclear proliferation marker stain (blue). Scale bar: 100 µm.
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Figure 6. Average area of GFP and β-tubulin III (Tuj1) expression correlates with the stereological counts of GFP+ ESNPCs and
NeuN ESNPCs. (A) The average area of GFP expression was significantly larger in groups where the ESNPCs were transplanted
in fibrin scaffolds containing NT-3 and PDGF [10EB + DS + GF (n = 8) and 10EB + GF no DS (n = 8)] compared to ESNPCs
transplanted alone and in fibrin scaffolds [10EB no Fibrin (n = 6) and 10EB + Fibrin (n = 8)]. Error bars are SE. *p < 0.05 versus.
10EB no Fibrin and 10EB + Fibrin. (B) The average area of GFP and Tuj1 coexpression was significantly larger in the group
where ESNPCs were transplanted in fibrin scaffolds containing NT-3, PDGF, and the HBDS [10EB + DS + GF (n = 8)] when
compared to the 10EB no Fibrin and 10EB + Fibrin groups. Error bars represent SEM. *p < 0.05 versus 10EB no Fibrin (n = 6)
and 10EB + Fibrin (n = 8).

10EB + GF no DS, p = 0.07) (Fig. 7C). The average are
of SSEA-1 expression was significantly greater when
ESNPCs were transplanted in a fibrin scaffold containing the growth factors, and the HBDS when compared
to all other experimental groups (10EB + DS + GF vs.
10EB + GF no DS, 10EB no Fibrin, 10EB + Fibrin, p <
0.05) (Fig. 7D).
Macrophage/Microglia Profile
The host reaction to an implanted material can have
a significant effect on the intended function of the material. To evaluate the tissue response of the transplants, a
profile of macrophage/microglia presence adjacent to
the lesion site was used to assess inflammation. A program was developed that analyzed the intensity of ED1
staining as a function of distance from the lesion border.
In all of the experimental groups, ED1-positive cells accumulated at the lesion border. The groups with ESNPCs
transplanted directly in the lesion site (10EB no Fibrin),
ESNPCS in fibrin (10EB + Fibrin), and ESNPCS in fibrin with GF and HBDS (10EB + DS + GF) exhibited a
decrease in ED1 staining intensity compared to the untreated control group, immediately adjacent to the lesion
border (0 µm rostral and caudal, p < 0.05) (Fig. 3A).
There was no significant difference in ED1 intensity between the ESNPCs in fibrin with GF without HBDS
(10EB + GF no DS) when compared to the untreated
control (p < 0.09) (Fig. 3B).
DISCUSSION
The in vivo survival and differentiation of transplanted ESNPCs was evaluated in a subacute model of

SCI. The transplantation of ESNPCs in fibrin scaffolds
containing NT-3 and PDGF increased overall cell survival and proliferation by X-fold over 2 weeks. Furthermore, the transplantation of ESNPCs in fibrin scaffolds
containing GF and HBDS increased the number of
ESNPC-derived NeuN+ neurons (1.2 × 105 NeuN+ cells
in the 10EB + GF + DS group compared to <0.25 × 105
NeuN+ cells in the groups without GF). Others have
found that NPC transplantation into the injured spinal
cord results in poor cell survival and differentiation into
a predominately glial fate (7,8,22,33). Previously, ESNPCs
induced using the same 4−/4+ RA protocol were injected into a crush model of SCI 9 days after injury and
found to promote a modest increase in functional recovery (21). However, the authors found that cell survival
was poor (⬃10%), and few of the surviving cells differentiated into neurons (⬃8%). The findings in our current
study are significant because they demonstrate the ability
to enhance the survival and differentiation of NPCs into
neurons after transplantation into the injured spinal cord.
ESNPCs in fibrin scaffolds containing GF exhibited
robust survival and proliferation at 2 weeks following
implantation into a subacute model of SCI. In vitro studies evaluating NT-3 and PDGF, at the same total doses
used in this study, found that the combination resulted
in increased survival of ESNPCs at 2 weeks (32). Consistent with these in vitro findings, our study found that
the stereological count of ESNPCs with GF (with or
without HBDS) was higher than either ESNPCs implanted directly into the lesion site or in fibrin without
GF after transplantation. The stereological counts estimate that the addition of GF increased the total cell
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Figure 7. The conditions for ESNPC transplantation had a significant effect of differentiation. (A) The average area of GFP and
O4 coexpression for ESNPCs that differentiated into oligodendrocytes was significantly increased in ESNPCs transplanted within
fibrin scaffolds containing NT-3, PDGF, and the HBDS [10EB + DS + GF (n = 8)] compared to all other groups [*p < 0.05 compared to 10EB no Fibrin (n = 6), 10EB + Fibrin (n = 8), and 10EB + GF no DS (n = 8)]. (B) The average area of GFP and GFAP
coexpression for ESNPCs that differentiated into astrocytes was significantly increased in ESNPCs transplanted within fibrin scaffolds containing NT-3 and PDGF [10EB + DS + GF (n = 8) and 10EB + GF no DS (n = 8)] compared to ESNPCs transplanted
alone and in fibrin scaffolds [10EB no Fibrin (n = 6) and 10EB + Fibrin (n = 8)] [*p < 0.05 vs. 10EB no Fibrin (n = 6) and 10EB +
Fibrin (n = 8)]. (C) The average area of GFP and nestin coexpression for ESNPCs remained undifferentiated was not significantly
between all of the groups. (D) The average area of GFP and SSEA-1 coexpression for transplanted mouse embryonic stem cells
that remained undifferentiated was significantly greater when transplanted in fibrin scaffolds containing growth factor and the
HBDS when compared to all other experimental groups (*p < 0.05 vs. 10EB no Fibrin, 10EB + fibrin, and 10EB + DS + GF). Error
bars from all graphs represent SEM.

number approximately 10-fold over the initial estimated
cell number in 2 weeks. In contrast, those ENSPCs embedded in fibrin scaffolds alone only increased roughly
twofold over the same time period. Our findings are
consistent with other studies that have shown that the
combination of NT-3 and PDGF promotes NPC survival
in models of CNS disease (14), and PDGF specifically
promotes NPC proliferation (11,12).
The incorporation of the HBDS in fibrin scaffolds
containing GF and ESNPCs resulted in an increase in
the number of ENSPC-derived NeuN+ cells. These findings are consistent with in vitro studies that found NT3 and PDGF delivered from the HBDS increased the

percentage ESNPCs that differentiated into neurons
(32). It has been shown that soluble NT-3 promotes the
differentiation of human ESCs into neurons in culture
and treatment of NPCs with NT-3 results in the formation of bipolar neurons (19,20). The stereological count
of NeuN+ neurons derived from ESNPCs in fibrin with
GF and no HBDS was not different from the other
groups. These results suggest that controlled delivery of
NT-3 and PDGF using the HBDS was required for the
increase in neuronal differentiation compared groups
without GF.
The addition of the HBDS could have affected the
differentiation of the ESNPCs. Heparin alone in the cul-
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ture medium of ESCs and NPCs has been shown to increase proliferation through secondary interactions with
fibroblast growth factor (FGF) that enhance FGF’s mitotic activity (5,15). Willerth et al. found that using the
same concentration of heparin found in the HBDS resulted in a decrease in astrocytes differentiation (32). In
our study, the HBDS had no effect on astrocytes differentiation of ESNPCs, and thus it is unlikely that direct
interaction between heparin and the ESNPCs resulted in
an increase in NeuN+ neurons.
As with heparin, the presence of the heparin-binding
peptide from the HBDS could have an effect on ESNPCs
differentiation. Others have demonstrated the ability of
cell adhesion sequences from laminin to promote differentiation of NPCs (28). However, evaluation of the
HBDS in vitro showed that the affinity peptide alone in
culture had no effect on neuronal differentiation (32).
Based on these previous results, it is unlikely that interaction of ESNPCs with the heparin-binding peptide in
the HBDS accounted for the increase in NeuN+ neurons.
A more likely explanation for the observed increase in
NeuN+ neurons with the HBDS is its ability to sequester
NT-3 and PDGF to the fibrin scaffold (29,32). Furthermore, the HBDS could also have increased the residence
time of other endogenously produced GFs within the fibrin scaffolds.
A method to analyze the differentiation of transplanted ESNPCs was developed to compliment the stereological analysis performed in this study. With the exception of NeuN, the cell differentiation markers used in
this study were cell surface (SSEA-1/O4) or intracellular
proteins (nestin, Tuj1, GFAP) that are expressed in different locations within the cell. As a consequence, if the
cell of interest is adjoining another cell with the same
marker it is difficult to delineate the boundary between
each independent cell and thus impossible to make an
accurate stereological count. A program was written that
evaluates the total area of pixels that are positive for
both green fluorescent protein (GFP) and the neural
marker of interest. While this method of analysis does
not indicate a specific number of cells stained positive
for a given marker, it does quantify the average area of
expression for each given marker. The area of expression can then be compared between experimental groups
to determine a difference in expression between groups.
To assure that the method correlated to the stereological
counts of the GFP+ and NeuN+ cells, we analyzed the
amount of GFP expression for transplanted ESNPCs and
Tuj1 for neurons. The analysis of average area of expression for GFP and Tuj1 predicted the same trends
obtained with the stereological counts for transplanted
ESNPCs that expressed the neuronal marker NeuN and
GFP; thus, for a given marker a greater area of expression correlated with a greater number of cells, as ex-
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pected. However, this method does not allow correlations between markers (e.g., area of Tuj1 vs. GFAP) that
could be performed with absolute cell number counts
from stereology.
By analyzing the average area of GFP+ O4 expression
using this method, we found that ESNPC-derived cells
in fibrin with GF and the HBDS showed increased O4
expression compared to all other groups. The combination of the two GF and the HBDS was found to increase
oligodendrocyte differentiation in vitro ESNPCs (32).
The increased O4 expression seen in the 10EB + DS +
GF group suggests that the presence of the controlled
delivery of GF promotes oligodendrocyte differentiation. ESNPCs in fibrin containing GF with or without
HBDS showed an increase in the average area of GFAP
expression compared to groups without GF. In vitro
studies found that the addition of the HBDS decreased
astrocytes differentiation compared to controls that were
cultured without the GF (32). While the addition of the
GF resulted in increased GFAP and O4 staining, the
neuronal markers were more widely expressed than glial
markers on ESNPC-derived cells after transplantation.
Staining with the mouse ESC marker SSEA-1 revealed a moderate amount of expression of the ESC
marker by the transplanted cells. This is not surprising
considering the RA induction protocol only results in a
population of cells that are 70% nestin-positive ESNPCs
(31). Quantification of the average area of SSEA-1 expression revealed differences between experimental
groups. The 10EB + DS + GF group average are of SSEA1 expression was greater than all other experimental
groups. Previously, it has been shown that PDGF can
enhance the survival and proliferation of SSEA-1-positive mouse ESCs in in vitro culture (31). It follows that
in this study the presence of the growth factors and the
HBDS enhanced the survival and proliferation of SSEA1-positive mouse ESCs.
Analysis of the average area of marker expression is
not the same as stereological counts of cells. As mentioned above, the quantification of proteins that are located in different places within the cell make comparison of areas between different antibodies inaccurate
(e.g., area positive for Tuj1 vs. GFAP). Likewise, the
summation of the different average areas of expression
(Tuj1, GFAP, nestin, and SSEA-1) are not expected to
add up to the average area of expression of GFP+ transplanted ESNPCs and they do not. It is possible that the
differences in area are a result of the quantification
method and it is possible that some of the GFP+ cells
are expressing markers other than those assayed in this
study. Based on the type of analysis that was utilized in
this study, it is impossible to tell. However, the goal of
the analysis was to look at the differential effects these
growth factors have on differentiation of the ESNPCs
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into the three neural subtypes (neurons, oligodendrocytes, and astrocytes). The foreign body response to a
transplanted material can drastically affect the function
of the material in vivo. We analyzed the intensity of
macrophage/microglia staining surrounding the implants
assess any adverse response to the ESNPC containing
scaffolds. In previous studies, we have found that fibrin
scaffolds alone do not induce an adverse response in the
surrounding host tissue based on the presence of macrophage/microglia (17). In this study we found that three
of the four groups that were treated with ESNPCs had a
decrease in the intensity of macrophage staining surrounding the lesion site compared to the control group
(received the same surgical procedures but no treatment). Transplanted NPCs have been found to be neuroprotective and increase the viability of neural tissue during and following injury to the CNS (1). Similarly, if
the transplanted ESNPCs increase survival of host tissue, then that may have led to the decrease in macrophage/microglia staining surrounding the lesion.
CONCLUSIONS
Here we have investigated the feasibility of transplanting ESNPCs within fibrin scaffolds containing GF
and a HBDS to increase cell survival and direct their
differentiation following transplantation into the injured
spinal cord. Transplantation of the ESNPCs in fibrin
scaffolds containing NT-3 and PDGF enhanced their
survival and proliferation 2 weeks after transplantation.
Also, the addition of a HBDS resulted in an increase in
the number of ESNPCs that differentiated into NeuN+
neurons. These results are the first step toward a larger
goal of enhancing functional recovery following SCI by
repopulating the damaged cord with neurons and oligodendrocytes that can increase local plasticity. Finally,
the method of implantation outlined in this work could
be used to increase the survival and differentiation of
transplanted cells for other cell therapies.
ACKNOWLEDGMENTS: This study was supported by NIH
RO1 NS051454. The authors thank Dan Hunter and Dr. Susan
Mackinnon for the use of their cryostat and stereology equipment.

REFERENCES
1. Aharonowiz, M.; Einstein, O.; Fainstein, N.; Lassmann,
H.; Reubinoff, B.; Ben-Hur, T. Neuroprotective effect of
transplanted human embryonic stem cell-derived neural
precursors in an animal model of multiple sclerosis. PLoS
ONE 3(9):e3145; 2008.
2. Bain, G.; Kitchens, D.; Yao, M.; Huettner, J. E.; Gottlieb,
D. I. Embryonic stem cells express neuronal properties in
vitro. Dev. Biol. 168(2):342–357; 1995.
3. Bareyre, F. M. Neuronal repair and replacement in spinal
cord injury. J. Neurol. Sci. 265(1–2):63–72; 2008.
4. Bareyre, F. M.; Kerschensteiner, M.; Raineteau, O.;
Mettenleiter, T. C.; Weinmann, O.; Schwab, M. E. The
injured spinal cord spontaneously forms a new intraspinal
circuit in adult rats. Nat. Neurosci. 7(3):269–277; 2004.

5. Caldwell, M. A.; Svendsen, C. N. Heparin, but not other
proteoglycans potentiates the mitogenic effects of FGF-2
on mesencephalic precursor cells. Exp. Neurol. 152(1):1–
10; 1998.
6. Cao, Q. L.; Howard, R. M.; Dennison, J. B.; Whittemore,
S. R. Differentiation of engrafted neuronal-restricted precursor cells is inhibited in the traumatically injured spinal
cord. Exp. Neurol. 177(2):349–359; 2002.
7. Cao, Q. L.; Zhang, Y. P.; Howard, R. M.; Walters, W. M.;
Tsoulfas, P.; Whittemore, S. R. Pluripotent stem cells engrafted into the normal or lesioned adult rat spinal cord
are restricted to a glial lineage. Exp. Neurol. 167(1):48–
58; 2001.
8. Chow, S. Y.; Moul, J.; Tobias, C. A.; Himes, B. T.; Liu,
Y.; Obrocka, M.; Hodge, L.; Tessler, A.; Fischer, I. Characterization and intraspinal grafting of EGF/bFGF-dependent neurospheres derived from embryonic rat spinal cord.
Brain Res. 874(2):87–106; 2000.
9. Courtine, G.; Song, B.; Roy, R. R.; Zhong, H.; Herrmann,
J. E.; Ao, Y.; Qi, J.; Edgerton, V. R.; Sofroniew, M. V.
Recovery of supraspinal control of stepping via indirect
propriospinal relay connections after spinal cord injury.
Nat. Med. 14(1):69–74; 2008.
10. Eriksson, P. S.; Perfilieva, E.; Bjork-Eriksson, T.; Alborn,
A. M.; Nordborg, C.; Peterson, D. A.; Gage, F. H. Neurogenesis in the adult human hippocampus. Nat. Med. 4(11):
1313–1317; 1998.
11. Erlandsson, A.; Brannvall, K.; Gustafsdottir, S.; Westermark, B.; Forsberg-Nilsson, K. Autocrine/paracrine platelet-derived growth factor regulates proliferation of neural
progenitor cells. Cancer Res. 66(16):8042–8048; 2006.
12. Erlandsson, A.; Enarsson, M.; Forsberg-Nilsson, K. Immature neurons from CNS stem cells proliferate in response to platelet-derived growth factor. J. Neurosci.
21(10):3483–3491; 2001.
13. Fawcett, J. W.; Asher, R. A. The glial scar and central
nervous system repair. Brain Res. Bull. 49(6):377–391;
1999.
14. Fressinaud, C. Repeated injuries dramatically affect cells
of the oligodendrocyte lineage: Effects of PDGF and NT3 in vitro. Glia 49(4):555–566; 2005.
15. Furue, M. K.; Na, J.; Jackson, J. P.; Okamoto, T.; Jones,
M.; Baker, D.; Hata, R.; Moore, H. D.; Sato, J. D.;
Andrews, P. W. Heparin promotes the growth of human
embryonic stem cells in a defined serum-free medium.
Proc. Natl. Acad. Sci. USA 105(36):13409–13414; 2008.
16. Jain, A.; Kim, Y. T.; McKeon, R. J.; Bellamkonda, R. V.
In situ gelling hydrogels for conformal repair of spinal
cord defects, and local delivery of BDNF after spinal cord
injury. Biomaterials 27(3):497–504; 2006.
17. Johnson, P. J.; Parker, S. R.; Sakiyama-Elbert, S. E. Fibrin-based tissue engineering scaffolds enhance neural fiber sprouting and delay the accumulation of reactive
astrocytes at the lesion in a subacute model of spinal cord
injury. J. Biomed. Mater. Res. 92A:152–163; 2010.
18. Karimi-Abdolrezaee, S.; Eftekharpour, E.; Wang, J.;
Morshead, C. M.; Fehlings, M. G. Delayed transplantation
of adult neural precursor cells promotes remyelination and
functional neurological recovery after spinal cord injury.
J. Neurosci. 26(13):3377–3389; 2006.
19. Lachyankar, M. B.; Condon, P. J.; Quesenberry, P. J.;
Litofsky, N. S.; Recht, L. D.; Ross, A. H. Embryonic precursor cells that express Trk receptors: Induction of different cell fates by NGF, BDNF, NT-3, and CNTF. Exp.
Neurol. 144(2):350–360; 1997.
20. Levenberg, S.; Burdick, J. A.; Kraehenbuehl, T.; Langer,

ENHANCED NPC SURVIVAL AND DIFFERENTIATION FOR SCI

21.

22.
23.

24.

25.

26.

R. Neurotrophin-induced differentiation of human embryonic stem cells on three-dimensional polymeric scaffolds.
Tissue Eng. 11(3–4):506–512; 2005.
McDonald, J. W.; Liu, X. Z.; Qu, Y.; Liu, S.; Mickey,
S. K.; Turetsky, D.; Gottlieb, D. I.; Choi, D. W. Transplanted embryonic stem cells survive, differentiate and
promote recovery in injured rat spinal cord. Nat. Med.
5(12):1410–1412; 1999.
McDonald, J. W.; Sadowsky, C. Spinal-cord injury. Lancet 359(9304):417–425; 2002.
McKeon, R. J.; Schreiber, R. C.; Rudge, J. S.; Silver, J.
Reduction of neurite outgrowth in a model of glial scarring following CNS injury is correlated with the expression of inhibitory molecules on reactive astrocytes. J.
Neurosci. 11(11):3398–3411; 1991.
Morshead, C. M.; Reynolds, B. A.; Craig, C. G.; McBurney, M. W.; Staines, W. A.; Morassutti, D.; Weiss, S.; van
der Kooy, D. Neural stem cells in the adult mammalian
forebrain: A relatively quiescent subpopulation of subependymal cells. Neuron 13(5):1071–1082; 1994.
Nakamura, M.; Okano, H.; Toyama, Y.; Dai, H. N.; Finn,
T. P.; Bregman, B. S. Transplantation of embryonic spinal
cord-derived neurospheres support growth of supraspinal
projections and functional recovery after spinal cord injury in the neonatal rat. J. Neurosci. Res. 81(4):457–468;
2005.
Rudge, J. S.; Silver, J. Inhibition of neurite outgrowth on
astroglial scars in vitro. J. Neurosci. 10(11):3594–3603;
1990.

101

27. Sakiyama-Elbert, S. E.; Hubbell, J. A. Development of fibrin derivatives for controlled release of heparin-binding
growth factors. J. Control. Release 65(3):389–402; 2000.
28. Silva, G. A.; Czeisler, C.; Niece, K. L.; Beniash, E.;
Harrington, D. A.; Kessler, J. A.; Stupp, S. I. Selective
differentiation of neural progenitor cells by high-epitope
density nanofibers. Science 303(5662):1352–1355; 2004.
29. Taylor, S. J.; Rosenzweig, E. S.; McDonald, 3rd, J. W.;
Sakiyama-Elbert, S. E. Delivery of neurotrophin-3 from
fibrin enhances neuronal fiber sprouting after spinal cord
injury. J. Control. Release 113(3):226–235; 2006.
30. Willerth, S. M.; Arendas, K. J.; Gottlieb, D. I.; SakiyamaElbert, S. E. Optimization of fibrin scaffolds for differentiation of murine embryonic stem cells into neural lineage
cells. Biomaterials 27(36):5990–6003; 2006.
31. Willerth, S. M.; Faxel, T. E.; Gottlieb, D. I.; SakiyamaElbert, S. E. The effects of soluble growth factors on embryonic stem cell differentiation inside of fibrin scaffolds.
Stem Cells 25(9):2235–2244; 2007.
32. Willerth, S. M.; Rader, A.; Sakiyama-Elbert, S. E. The
effect of controlled growth factor delivery on embryonic
stem cell differentiation inside fibrin scaffolds. Stem Cell
Res. 1:205–218; 2008.
33. Zahir, T.; Nomura, H.; Guo, X. D.; Kim, H.; Tator, C.;
Morshead, C.; Shoichet, M. Bioengineering neural stem/
progenitor cell-coated tubes for spinal cord injury repair.
Cell Transplant. 17(3):245–254; 2008.

